On September 25, 2017 Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, reported that four abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 32nd Annual Meeting, November 8-12, 2017 in National Harbor, Maryland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral and poster presentation information are as follows:

Novel Biomarkers in Next-generation Cancer Vaccines

Public NY-ESO-1 specific TCRs as novel biomarkers for immune monitoring of NY-ESO-1 positive cancer patients

Oral Presentation/ SITC (Free SITC Whitepaper) Pre-Conference Program
Session title: Immuno-Oncology Biomarkers: Today’s Imperatives for Tomorrow’s Needs
Date: November 8, 2017
Time: 8 a.m. to 12:30 p.m.
Presenter: Hailing Lu, MD, PhD, Principal Scientist, Immune Design

Poster Presentation:
Poster Number: P58
Date: Saturday, November 11, 2017
Time: 12:30 — 2 p.m. and 6:30 — 8 p.m.
Presenter: Hailing Lu, MD, PhD, Principal Scientist, Immune Design

Combination Therapy (Cancer Vaccine + Intratumoral Immunization):

G100 and ZVex-based combination immunotherapy induces near complete regression of established glioma tumors in mice

Poster Number: P256
Date: Saturday, November 11, 2017
Time: 12:30 — 2 p.m. and 6:30 — 8 p.m.
Presenter: Tina Chang Albershardt, PhD, Scientist II, Immune Design

Multi-Target Cancer Vaccines:

Transduction of MAGE-A1, A3, A4, A10 and IL-12 by ZVex, a dendritic cell targeting platform induces robust multi-antigen T-cell immune responses without antigenic interference or immunodominance

Poster Number: P127
Date: Friday, November 10, 2017
Time: 12:30 — 2 p.m. and 6:30 — 8 p.m.
Presenter: Jardin Leleux, Postdoctoral Researcher, Immune Design

Next-Generation Intratumoral Vaccination Using ZVex:

Intratumoral expression of IL12 using the ZVex dendritic cell-targeting lentiviral vector exerts potent anti-tumor effects via induction of multiple immune effectors, including CD8 T cell responses

Poster Number: P401
Date: Friday, November 10, 2017
Time: 12:30 — 2 p.m. and 6:30 — 8 p.m.
Presenter: Tina Chang Albershardt, PhD, Scientist II, Immune Design